Benjamin Primack

Benjamin Primack is a skilled scientist with extensive experience in biomedical research, particularly in immunotherapy and CAR T-cell dynamics. Currently at Obsidian Therapeutics since January 2018, Benjamin has advanced through various roles, including Senior Associate Scientist and Associate Scientist. Prior to Obsidian, Benjamin held positions at Novartis Institutes for BioMedical Research, where responsibilities included executing in vivo models and analyzing CAR T-cell responses, and Dana-Farber Cancer Institute, focusing on in vivo techniques related to xenograft models. Benjamin's research acumen began with a Bachelor's degree in Biology from the University of Rochester, followed by a Master's degree in Pharmacology from Northeastern University.